Genelux SVP sells shares to cover tax bill

GENELUX Corp senior vice president sells small block of shares for taxes.

Rhea-AI Filing Summary

GENELUX Corp senior vice president sells small block of shares for taxes. SVP of Clinical Development Yu Yong sold 906 shares of common stock at $2.42 per share in an open-market transaction to cover estimated taxes from vesting restricted stock units. After this sale, Yu Yong directly holds 144,938 shares.

Insider Trade Summary

Net Seller: 906 shares

Net Sell 1 txn

Insider Yu Yong

Role SVP, Clinical Development

Sold 906 shs ($2K)

Type	Security	Shares	Price	Value
Sale	Common Stock	906	$2.42	$2K

Holdings After Transaction: Common Stock — 144,938 shares (Direct)

Footnotes (1)

1. F1. Represents shares sold by the Reporting Person to cover estimated taxes to be paid by the Reporting Person in connection with the vesting of restricted stock units.

FAQ

What insider transaction did GENELUX Corp (GNLX) report for Yu Yong?

GENELUX reported that SVP of Clinical Development Yu Yong sold 906 shares of common stock. The shares were sold in an open-market transaction to cover estimated taxes related to the vesting of restricted stock units.

At what price did Yu Yong sell GENELUX (GNLX) shares in this Form 4?

Yu Yong sold 906 shares of GENELUX common stock at $2.42 per share. The transaction is characterized as an open-market or private sale and was undertaken to cover estimated tax obligations from restricted stock unit vesting.

How many GENELUX (GNLX) shares does Yu Yong hold after this Form 4 sale?

Following the reported sale, Yu Yong directly holds 144,938 shares of GENELUX common stock. This indicates the 906 shares sold represent a very small portion of the executive’s total reported direct holdings after the transaction.

Why did Yu Yong sell GENELUX (GNLX) shares according to the Form 4 footnote?

The footnote explains the 906 shares were sold to cover estimated taxes owed by Yu Yong. These tax obligations arose in connection with the vesting of restricted stock units, making the sale primarily a tax-related transaction rather than a discretionary portfolio move.

What role does Yu Yong hold at GENELUX Corp (GNLX)?

Yu Yong serves as Senior Vice President, Clinical Development at GENELUX Corp. This executive role focuses on the company’s clinical development activities, and the Form 4 reports personal equity transactions in GENELUX common stock related to that position.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/26/2026 - 05:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Yu Yong

(Last) (First) (Middle)

C/O GENELUX CORPORATION

2625 TOWNSGATE ROAD, SUITE 230

(Street)

WESTLAKE VILLAGE CALIFORNIA 91361

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
GENELUX Corp [ GNLX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Clinical Development

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/24/2026		S(1)		906	D	$2.42	144,938	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares sold by the Reporting Person to cover estimated taxes to be paid by the Reporting Person in connection with the vesting of restricted stock units.

	/s/ Thomas Zindrick, J.D., Attorney-in-Fact	03/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)